{"id":457185,"date":"2021-03-15T07:00:43","date_gmt":"2021-03-15T11:00:43","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=457185"},"modified":"2021-03-15T07:00:43","modified_gmt":"2021-03-15T11:00:43","slug":"genetron-health-to-present-at-science-aaas-webinar-about-early-cancer-screening-on-march-31","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-science-aaas-webinar-about-early-cancer-screening-on-march-31\/","title":{"rendered":"Genetron Health to Present at Science\/AAAS Webinar About Early Cancer Screening on March 31"},"content":{"rendered":"

<\/p>\n

Genetron Health to Present at Science\/AAAS Webinar About Early Cancer Screening on March 31<\/b><\/p>\n

BEIJING–(BUSINESS WIRE<\/a>)–
\nGenetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d, NASDAQ: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the company will present at one of the Science\/AAAS Webinar Series, \u201cEarly cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment\u201d.\n<\/p>\n

\nThe webinar will be available online on March 31. It is now open for registration at:
\n
https:\/\/www.sciencemag.org\/custom-publishing\/webinars\/early-cancer-screening-today-and-tomorrow-exploring-liquid-biopsy<\/a><\/p>\n

\nGenetron Health\u2019s Chief Technology Officer, Dr. Yuchen Jiao, will discuss the company\u2019s advanced early cancer screening technology and join the conversation with Dr. Anne Marie Lennon, Director of the Johns Hopkins Division of Gastroenterology and Hepatology and a professor of Medicine at the Johns Hopkins University School of Medicine.\n<\/p>\n

\nEarly detection of a cancer is critical to its characterization, treatment, and eventual elimination. Many cancers, however, grow undetected due to the traditional lack of sufficiently accurate or sensitive means to detect them. With recent advances in the detection of cancer-specific DNA in the blood\u2014so-called cell-free DNA, or cfDNA, there is hope that liquid biopsies could provide a minimally invasive way to identify primary cancers much sooner, as well as alert doctors to relapse following treatment by identifying minimal residual disease.\n<\/p>\n

\nThis webinar will discuss these advances in early cancer screening, such as recent successes and new methodologies for cfDNA detection and analysis. Topics will include:\n<\/p>\n